Showing 4231-4240 of 6661 results for "".
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board&#
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- ASDSA Releases New Sun-Safety Model Legislationhttps://practicaldermatology.com/news/asdsa-releases-new-sun-safety-model-legislation/2458548/New model legislation from American Society for Dermatologic Surgery Association (ASDSA) provides state governments with a framework to permit the use of sunscreens in school and camp settings. The
- Robert Grant No Longer CEO of Alphaeonhttps://practicaldermatology.com/news/robert-grant-no-longer-ceo-of-alphaeon/2458550/Robert Grant is no longer CEO of Alphaeon, our sister site, Eyewiretoday.com has learned. After 3 years at
- Cynosure Receives FDA Clearance to Market PicoSure Energy Delivery System for Tattoos and Pigmented Lesionshttps://practicaldermatology.com/news/cynosure-receives-fda-clearance-to-market-picosure-energy-delivery-system-for-tattoos-and-pigmented-lesions/2458554/The FDA granted clearance to Cynosure to market a new Laser Delivery System for PicoSure. Together with the FDA cleared 532nm and 755nm wavelengths, Cynosure's new 1064nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks i
- Dr. Brandt's Legacy Lives on with New Dr. Brandt® Skincare Advisory Boardhttps://practicaldermatology.com/news/dr-brandts-legacy-lives-on-with-new-dr-brandt-skincare-advisory-board/2458563/Dr. Brandt® Skincare is rolling out a new Advisory Board to elevate the brand and honor Dr. Brandt’s legacy of innovation in dermatology. Frederick Brandt died on April 5, 2015 in his home in Coconut Grove, Florida. The first
- Untreated Sleep Apnea Linked to Melanoma Aggressionhttps://practicaldermatology.com/news/untreated-sleep-apnea-linked-to-melanoma-aggressiveness/2458564/Untreated severe obstructive sleep apnea (OSA) is linked to increased aggressiveness of malignant cutaneous melanoma, according to research presented at the American Thoracic Society 2016 International Conference in San Francisco. The study involved 412 patients, average age 55.8, w